EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites

Talya L Dayton, Nicolas Alcala, Laura Moonen, Lisanne den Hartigh, Veerle Geurts, Lise Mangiante, Lisa Lap, Antonella F M Dost, Joep Beumer, Sonja Levy, Rachel S van Leeuwaarde, Wenzel M Hackeng und 24 weitere

Cancer Cell · 2023-12 · 41 (12) · 2083-2099.e9

DOI: 10.1016/j.ccell.2023.11.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-12. Verfasst von Talya L Dayton und 35 weiteren Autor:innen. Beteiligte Einrichtung: Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrec…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Lung Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, European Molecular Biology Organization, Institut National Du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for patients with NENs are limited, in part due to lack of accurate models. We establish patient-derived tumor organoids (PDTOs) from pulmonary NETs and derive PDTOs from an understudied subtype of NEC, large cell neuroendocrine carcinoma (LCNEC), arising from multiple body sites. PDTOs maintain the gene expression patterns, intra-tumoral heterogeneity, and evolutionary processes of parental tumors. Through hypothesis-driven drug sensitivity analyses, we identify ASCL1 as a potential biomarker for response of LCNEC to treatment with BCL-2 inhibitors. Additionally, we discover a dependency on EGF in pulmonary NET PDTOs. Consistent with these findings, we find that, in an independent cohort, approximately 50% of pulmonary NETs express EGFR. This study identifies an actionable vulnerability for a subset of pulmonary NETs, emphasizing the utility of these PDTO models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsCarcinoma, NeuroendocrineLung NeoplasmsPancreatic NeoplasmsHumans

Stichwörter der Autor:innen

biomarkercancercell neuroendocrine carcinomagenomicsgrowth factor depenenciesintra-tumor heterogeneitylung cancerneuroendocrine tumorlargeorganoidstumor evolution

Autor:innen und Institutionen

  • Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands. Electronic address: ta…
  • Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France.
  • Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands.
  • Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands.
  • Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.

Förderung

  • World Health Organization
  • European Molecular Biology Organization
  • Institut National Du Cancer
  • Neuroendocrine Tumor Research Foundation
  • Worldwide Cancer Research
  • Cancer Couch Foundation
  • European Commission
  • Ligue Contre le Cancer

Zitieren

APA

Dayton, T. L., Alcala, N., Moonen, L., den Hartigh, L., Geurts, V., Mangiante, L., Lap, L., Dost, A. F. M., Beumer, J., Levy, S., van Leeuwaarde, R. S., Hackeng, W. M., Samsom, K., Voegele, C., Sexton-Oates, A., Begthel, H., Korving, J., Hillen, L., Brosens, L. A. A., …, & Clevers, H. (2023). Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer Cell, 41(12), 2083-2099.e9. https://doi.org/10.1016/j.ccell.2023.11.007

Vancouver

Dayton TL, Alcala N, Moonen L, den Hartigh L, Geurts V, Mangiante L, et al. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer Cell. 2023;41(12):2083-2099.e9. doi:10.1016/j.ccell.2023.11.007

BibTeX
@article{Dayton2023,
  author = {Dayton, Talya L and Alcala, Nicolas and Moonen, Laura and den Hartigh, Lisanne and Geurts, Veerle and Mangiante, Lise and Lap, Lisa and Dost, Antonella F M and Beumer, Joep and Levy, Sonja and van Leeuwaarde, Rachel S and Hackeng, Wenzel M and Samsom, Kris and Voegele, Catherine and Sexton-Oates, Alexandra and Begthel, Harry and Korving, Jeroen and Hillen, Lisa and Brosens, Lodewijk A A and Lantuejoul, Sylvie and Jaksani, Sridevi and Kok, Niels F M and Hartemink, Koen J and Klomp, Houke M and Borel Rinkes, Inne H M and Dingemans, Anne-Marie and Valk, Gerlof D and Vriens, Menno R and Buikhuisen, Wieneke and van den Berg, José and Tesselaar, Margot and Derks, Jules and Speel, Ernst Jan and Foll, Matthieu and Fernández-Cuesta, Lynnette and Clevers, Hans},
  title = {Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {12},
  pages = {2083--2099.e9},
  doi = {10.1016/j.ccell.2023.11.007}
}
Kostenlos starten →